Olema Pharmaceuticals, Inc. 10-Q

Item 5. Other Information. During the fiscal quarter ended June 30, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as such terms are defined in Item 408(a) of Regulation S-K under the Exchange Act . 117 Table of Contents Item 6. Exhibits. Incorporated by Reference Exhibit Number Description Schedule Form File Number Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation. 8‑K 001‑39712 3.1 11/23/2020 3.2 Amended and Restated Bylaws. 8‑K 001‑39712 3.1 12/16/2022 10.1 Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy. 10-Q 001‑39712 10.3 05/12/2026 10.2¥ Lease Agreement, dated April 27, 2026, between KR Oyster Point II, LLC and Olema Pharmaceuticals, Inc. 10-Q 001‑39712 10.4 05/12/2026 10.3* Fourth Amendment to Loan and Security Agreement, dated July 1, 2026, between Silicon Valley Bank and Olema Pharmaceuticals, Inc. 31.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1*† Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 104 Cover page formatted as Inline XBRL and contained in Exhibit 101 * Filed herewith. † The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing. 118 Table of Contents ¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material. 119 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Olema Pharmaceuticals, Inc. Date: August 10, 2026 By: /s/ Sean Bohen, M.D., Ph.D. Sean Bohen, M.D., Ph.D. President and Chief Executive Officer ( Principal Executive Officer and Principal Financial Officer ) 120